Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02753127




Registration number
NCT02753127
Ethics application status
Date submitted
25/04/2016
Date registered
27/04/2016
Date last updated
15/11/2023

Titles & IDs
Public title
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Scientific title
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).
Secondary ID [1] 0 0
BB608-303CRC
Secondary ID [2] 0 0
CanStem303C
Universal Trial Number (UTN)
Trial acronym
CanStem303C
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Napabucasin
Treatment: Drugs - Fluorouracil
Treatment: Drugs - Leucovorin
Treatment: Drugs - Irinotecan
Treatment: Drugs - Bevacizumab

Experimental: Napabucasin plus FOLFIRI - Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.

Active Comparator: FOLFIRI - Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.


Treatment: Drugs: Napabucasin
Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).

Treatment: Drugs: Fluorouracil


Treatment: Drugs: Leucovorin


Treatment: Drugs: Irinotecan


Treatment: Drugs: Bevacizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Randomization to Date of Death from any cause or database cutoff date (28 Apr 2020) (Approximately 43 months)
Secondary outcome [1] 0 0
Progression-Free Survival (PFS)
Timepoint [1] 0 0
Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)
Secondary outcome [2] 0 0
Disease Control Rate (DCR)
Timepoint [2] 0 0
Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)
Secondary outcome [3] 0 0
Objective Response Rate (ORR)
Timepoint [3] 0 0
Randomization to Date of Death or until the date of first documented objective disease progression or database cutoff date (28 Apr 2020) (Approximately 43 months)
Secondary outcome [4] 0 0
Mean Change From Baseline for Global Health Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).
Timepoint [4] 0 0
From baseline at Time 2 (Cycle 5 Day 1), approximately 57 days and Time 4 (Cycle 9 Day 1), approximately 113 days
Secondary outcome [5] 0 0
Mean Change From Baseline for Physical Functioning Status at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1).
Timepoint [5] 0 0
From baseline at Time 2 (Cycle 5 Day 1) and Time 4 (Cycle 9 Day 1)
Secondary outcome [6] 0 0
Number of Patients With Adverse Events in the General Population
Timepoint [6] 0 0
All adverse event are collected from date of signed informed consent until 30 days after protocol treatment discontinuation. Outcome followed until study discontinuation up to 4 years

Eligibility
Key inclusion criteria
1. Written, signed consent for trial participation must be obtained from the patient
appropriately in accordance with applicable ICH guidelines and local and regulatory
requirements prior to the performance of any study specific procedure.

2. Must have histologically confirmed advanced CRC that is metastatic.

3. Must have failed treatment with one regimen containing a fluoropyrimidine, oxaliplatin
with or without bevacizumab for metastatic disease. All patients must have received a
minimum of 6 weeks of the first-line regimen that included bevacizumab (if
applicable), oxaliplatin and a fluoropyrimidine in the same cycle. Treatment failure
is defined as radiologic progression during or < 6 months after the last dose of
first-line therapy.

4. FOLFIRI therapy is appropriate for the patient and is recommended by the Investigator.

5. Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as
necessary to document all sites of disease performed within 21 days prior to
randomization. Patients with either measurable disease or non-measurable evaluable
disease are eligible.

6. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

7. Must be = 18 years of age.

8. For male or female patient of child bearing potential: Must agree to use contraception
or take measures to avoid pregnancy during the study and for 180 days for female and
male patients, of the final FOLFIRI dose. Patients who receive single agent
napabucasin without FOLFIRI must agree to use contraception or take measures to avoid
pregnancy during the study and for 30 days for female patients and 90 days for male
patients, of the final napabucasin dose.

9. Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy
test within 5 days prior to randomization. The minimum sensitivity of the pregnancy
test must be 25 IU/L or equivalent units of HCG.

10. Must have alanine transaminase (ALT) = 3 × institutional upper limit of normal (ULN)
[= 5 × ULN in presence of liver metastases] within 14 days prior to randomization.

11. Must have hemoglobin (Hgb) = 9.0 g/dL within 14 days prior to randomization. Must not
have required transfusion of red blood cells within 1 week of baseline Hgb assessment.

12. Must have total bilirubin = 1.5 × institutional ULN [= 2.0 x ULN in presence of liver
metastases] within 14 days prior to randomization.

13. Must have creatinine = 1.5 × institutional ULN or Creatinine Clearance > 50 ml/min (as
calculated by the Cockcroft-Gault equation (Chronic Kidney Disease Epidemiology
Collaboration [CKD-EPI]) within 14 days prior to randomization.

14. Must have absolute neutrophil count = 1.5 x 10^9/L within 14 days prior to
randomization.

15. Must have platelet count = 100 x 10^9/L within 14 days prior to randomization. Must
not have required transfusion of platelets within 1 week of baseline platelet
assessment.

16. Patient must have adequate nutritional status with Body Mass Index (BMI) > 18 kg/m^2
and body weight of > 40 kg with serum albumin > 3 g/dL.

17. Other baseline laboratory evaluations, listed in Section 6.0, must be done within 14
days prior to randomization.

18. Patient must consent to provision of, and Investigator(s) must confirm access to and
agree to submit a representative formalin fixed paraffin block of tumor tissue in
order that the specific biomarker assays may be conducted. Submission of the tissue is
to occur prior to randomization, unless approved by the Sponsor. Where local center
regulations prohibit submission of blocks of tumor tissue, two 2 mm cores of tumor
from the block and 10-30 unstained slides of whole sections of representative tumor
tissue are preferred. Where two 2 mm cores of tumor from the block are unavailable,
10-30 unstained slides of whole sections of representative tumor tissue alone are
acceptable. Where no previously resected or biopsied tumor tissue exists or is
available, on the approval of the Sponsor/designated CRO, the patient may still be
considered eligible for the study.

19. Patient must consent to provision of a sample of blood in order that the specific
correlative marker assays may be conducted.

20. Patients must be accessible for treatment and follow-up. Patients registered on this
trial must receive protocol treatment and be followed at the participating center.
This implies there must be reasonable geographical limits placed on patients being
considered for this trial. Investigators must ensure that the patients randomized on
this trial will be available for complete documentation of the treatment, response
assessment, adverse events, and follow-up.

21. Protocol treatment is to begin within 2 calendar days of patient randomization.

22. The patient is not receiving therapy in a concurrent clinical study and the patient
agrees not to participate in other interventional clinical studies during their
participation in this trial while on study treatment. Patients participating in
surveys or observational studies are eligible to participate in this study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Anti-cancer chemotherapy or biologic therapy if administered prior to the first
planned dose of study medication (napabucasin or FOLFIRI) within period of time
equivalent to the usual cycle length of the regimen. An exception is made for oral
fluoropyrimidines (e.g. capecitabine, S-1), where a minimum of 10 days since last dose
must be observed prior to the first planned dose of study medication. Standard dose of
bevacizumab (5 mg/kg) may be administered prior to FOLFIRI infusion, per Investigator
decision, for as long as permanent decision to include or exclude bevacizumab is made
prior to patient randomization. Radiotherapy, immunotherapy (including immunotherapy
administered for non-malignant diseaseneoplastic treatment purposes), or
investigational agents within four weeks of first planned dose of study medication,
with the exception of a single dose of radiation up to 8 Gy (equal to 800 RAD) with
palliative intent for pain control up to 14 days before randomization.

2. More than one prior chemotherapy regimen administered in the metastatic setting.

3. Major surgery within 4 weeks prior to randomization.

4. Patients with any known brain or leptomeningeal metastases are excluded, even if
treated.

5. Women who are pregnant or breastfeeding. Women should not breastfeed while taking
study treatment and for 4 weeks after the last dose of napabucasin or while undergoing
treatment with FOLFIRI and for 180 days after the last dose of FOLFIRI.

6. Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal
Investigator, would significantly impede the absorption of an oral agent (e.g.
intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric
and small intestine resection).

7. Unable or unwilling to swallow napabucasin capsules daily.

8. Prior treatment with napabucasin.

9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, clinically significant non-healing or healing wounds, symptomatic
congestive heart failure, unstable angina pectoris, clinically significant cardiac
arrhythmia, significant pulmonary disease (shortness of breath at rest or mild
exertion), uncontrolled infection or psychiatric illness/social situations that would
limit compliance with study requirements.

10. Known hypersensitivity to 5-fluorouracil/leucovorin

11. Known dihydropyrimidine dehydrogenase (DPD) deficiency

12. Known hypersensitivity to irinotecan

13. Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis)

14. Patients receiving treatment with St. John's wort or Phenytoin.

15. Patients who plan to receive yellow fever vaccine during the course of the study
treatment.

16. Abnormal glucuronidation of bilirubin, known Gilbert's syndrome

17. Patients with QTc interval > 470 milliseconds

18. For patients to be treated with a regimen containing bevacizumab:

- History of cardiac disease: congestive heart failure (CHF) > New York Heart
Association (NYHA) Class II; active coronary artery disease, myocardial
infarction within 6 months prior to study entry; unevaluated new onset angina
within 3 months or unstable angina (angina symptoms at rest) or cardiac
arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are
permitted).

- Current uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or
diastolic pressure > 90 mmHg despite optimal medical management) as well as prior
history of hypertensive crisis or hypertensive encephalopathy.

- History of arterial thrombotic or embolic events (within 6 months prior to study
entry)

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection,
symptomatic peripheral vascular disease)

- Evidence of bleeding diathesis or clinically significant coagulopathy

- Major surgical procedure (including open biopsy, significant traumatic injury,
etc.) within 28 days, or anticipation of the need for major surgical procedure
during the course of the study as well as minor surgical procedure (excluding
placement of a vascular access device or bone marrow biopsy) within 7 days prior
to study enrollment

- Proteinuria at screening as demonstrated by urinalysis with proteinuria = 2+
(patients discovered to have =2+ proteinuria on dipstick urinalysis at baseline
should undergo a 24 hour urine collection and must demonstrate = 1g of protein in
24 hours to be eligible).

- History of abdominal fistula, gastrointestinal perforation, peptic ulcer, or
intra-abdominal abscess within 6 months

- Ongoing serious, non-healing wound, ulcer, or bone fracture

- Known hypersensitivity to any component of bevacizumab

- History of reversible posterior leukoencephalopathy syndrome (RPLS)

- History of hypersensitivity to Chinese hamster ovary (CHO) cells or other human
or humanized recombinant antibodies.

19. Patients with a history of other malignancies except: adequately treated non-melanoma
skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
curatively treated with no evidence of disease for > 3 years.

20. Any active disease condition which would render the protocol treatment dangerous or
impair the ability of the patient to receive protocol therapy.

21. Any condition (e.g. psychological, geographical, etc.) that does not permit compliance
with the protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/05/2021
Sample size
Target
Accrual to date
Final
1253
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment hospital [2] 0 0
St Vincent's Hospital - Darlinghurst
Recruitment hospital [3] 0 0
St Vincent's hospital Melbourne - Fitzroy
Recruitment hospital [4] 0 0
Port Macquaries Base Hospital - Port Macquarie
Recruitment hospital [5] 0 0
Northern Cancer Institute - St Leonards
Recruitment hospital [6] 0 0
Sunshine Coast Hospital and Health Service - Nambour
Recruitment hospital [7] 0 0
Gold Coast University Hosptial - Southport
Recruitment hospital [8] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [9] 0 0
The Queen Elizabeth Hospital - Woodville
Recruitment hospital [10] 0 0
Bendigo Hospital - Bendigo
Recruitment hospital [11] 0 0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Recruitment hospital [12] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [13] 0 0
Western Health - Melbourne
Recruitment hospital [14] 0 0
Goulburn Valley Health - Shepparton
Recruitment hospital [15] 0 0
Prince of Wales Hospital - Randwick
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
3065 - Fitzroy
Recruitment postcode(s) [4] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [5] 0 0
2065 - St Leonards
Recruitment postcode(s) [6] 0 0
4560 - Nambour
Recruitment postcode(s) [7] 0 0
4215 - Southport
Recruitment postcode(s) [8] 0 0
5042 - Bedford Park
Recruitment postcode(s) [9] 0 0
5011 - Woodville
Recruitment postcode(s) [10] 0 0
3550 - Bendigo
Recruitment postcode(s) [11] 0 0
3199 - Frankston
Recruitment postcode(s) [12] 0 0
3084 - Heidelberg
Recruitment postcode(s) [13] 0 0
3021 - Melbourne
Recruitment postcode(s) [14] 0 0
3630 - Shepparton
Recruitment postcode(s) [15] 0 0
2031 - Randwick
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Hampshire
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
South Dakota
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
Belgium
State/province [30] 0 0
Antwerpen
Country [31] 0 0
Belgium
State/province [31] 0 0
Brussels Capital Region
Country [32] 0 0
Belgium
State/province [32] 0 0
Hainaut
Country [33] 0 0
Belgium
State/province [33] 0 0
Liège
Country [34] 0 0
Belgium
State/province [34] 0 0
Vlaams Brabant
Country [35] 0 0
Belgium
State/province [35] 0 0
West-Vlaanderen
Country [36] 0 0
Canada
State/province [36] 0 0
Alberta
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
China
State/province [39] 0 0
Beijing
Country [40] 0 0
China
State/province [40] 0 0
Henan
Country [41] 0 0
China
State/province [41] 0 0
Jiangsu
Country [42] 0 0
Czechia
State/province [42] 0 0
Královéhradecký Kraj
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno
Country [44] 0 0
Czechia
State/province [44] 0 0
Prague
Country [45] 0 0
France
State/province [45] 0 0
Angers
Country [46] 0 0
France
State/province [46] 0 0
Besançon
Country [47] 0 0
France
State/province [47] 0 0
Brest
Country [48] 0 0
France
State/province [48] 0 0
Clermont Ferrand
Country [49] 0 0
France
State/province [49] 0 0
Dijon
Country [50] 0 0
France
State/province [50] 0 0
Nantes
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Plérin
Country [53] 0 0
France
State/province [53] 0 0
Poitiers
Country [54] 0 0
France
State/province [54] 0 0
Rennes
Country [55] 0 0
France
State/province [55] 0 0
Saint-Herblain
Country [56] 0 0
Germany
State/province [56] 0 0
Bayern
Country [57] 0 0
Germany
State/province [57] 0 0
Sachsen-Anhalt
Country [58] 0 0
Germany
State/province [58] 0 0
Sachsen
Country [59] 0 0
Germany
State/province [59] 0 0
Bad Nauheim
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Hamburg
Country [62] 0 0
Germany
State/province [62] 0 0
Marburg
Country [63] 0 0
Germany
State/province [63] 0 0
Ulm
Country [64] 0 0
Hong Kong
State/province [64] 0 0
Hong Kong
Country [65] 0 0
Israel
State/province [65] 0 0
Afula
Country [66] 0 0
Israel
State/province [66] 0 0
Ashkelon
Country [67] 0 0
Israel
State/province [67] 0 0
Be'er Sheva
Country [68] 0 0
Israel
State/province [68] 0 0
Jerusalem
Country [69] 0 0
Israel
State/province [69] 0 0
Kefar Saba
Country [70] 0 0
Israel
State/province [70] 0 0
Petah tikva
Country [71] 0 0
Israel
State/province [71] 0 0
Safed
Country [72] 0 0
Israel
State/province [72] 0 0
Tel HaShomer
Country [73] 0 0
Israel
State/province [73] 0 0
Tel-Aviv
Country [74] 0 0
Italy
State/province [74] 0 0
Ancona
Country [75] 0 0
Italy
State/province [75] 0 0
Belluno
Country [76] 0 0
Italy
State/province [76] 0 0
Forli
Country [77] 0 0
Italy
State/province [77] 0 0
Ravenna
Country [78] 0 0
Italy
State/province [78] 0 0
Bologna
Country [79] 0 0
Italy
State/province [79] 0 0
Cremona
Country [80] 0 0
Italy
State/province [80] 0 0
Genova
Country [81] 0 0
Italy
State/province [81] 0 0
Milano
Country [82] 0 0
Italy
State/province [82] 0 0
Modena
Country [83] 0 0
Italy
State/province [83] 0 0
Napoli
Country [84] 0 0
Italy
State/province [84] 0 0
Piacenza
Country [85] 0 0
Italy
State/province [85] 0 0
Torino
Country [86] 0 0
Japan
State/province [86] 0 0
Aichi
Country [87] 0 0
Japan
State/province [87] 0 0
Chiba
Country [88] 0 0
Japan
State/province [88] 0 0
Ehime
Country [89] 0 0
Japan
State/province [89] 0 0
Hokkaido
Country [90] 0 0
Japan
State/province [90] 0 0
Hyogo
Country [91] 0 0
Japan
State/province [91] 0 0
Kanagawa
Country [92] 0 0
Japan
State/province [92] 0 0
Osaka
Country [93] 0 0
Japan
State/province [93] 0 0
Saitama
Country [94] 0 0
Japan
State/province [94] 0 0
Shizuoka
Country [95] 0 0
Japan
State/province [95] 0 0
Tokyo
Country [96] 0 0
Japan
State/province [96] 0 0
Fukuoka
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Daegu Gwang'yeogsi
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gyeonggido
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Incheon Gwang'yeogsi
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Seoul Teugbyeolsi
Country [101] 0 0
Netherlands
State/province [101] 0 0
Friesland
Country [102] 0 0
Netherlands
State/province [102] 0 0
Amsterdam
Country [103] 0 0
Netherlands
State/province [103] 0 0
Hoofddorp
Country [104] 0 0
Netherlands
State/province [104] 0 0
Maastricht
Country [105] 0 0
Netherlands
State/province [105] 0 0
Tilburg
Country [106] 0 0
Singapore
State/province [106] 0 0
Central Singapore
Country [107] 0 0
Spain
State/province [107] 0 0
Alicante
Country [108] 0 0
Spain
State/province [108] 0 0
Andalucía
Country [109] 0 0
Spain
State/province [109] 0 0
Asturias
Country [110] 0 0
Spain
State/province [110] 0 0
Barcelona
Country [111] 0 0
Spain
State/province [111] 0 0
Galicia
Country [112] 0 0
Spain
State/province [112] 0 0
Madrid
Country [113] 0 0
Spain
State/province [113] 0 0
Valencia
Country [114] 0 0
Spain
State/province [114] 0 0
Baleares
Country [115] 0 0
Spain
State/province [115] 0 0
Murcia
Country [116] 0 0
Spain
State/province [116] 0 0
Sevilla
Country [117] 0 0
Spain
State/province [117] 0 0
Zaragoza

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sumitomo Pharma America, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an international multi-center, prospective, open-label, randomized, adaptive design
phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly
FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic
colorectal cancer (CRC).
Trial website
https://clinicaltrials.gov/ct2/show/NCT02753127
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02753127